Natera, Inc. $NTRA Stock: Gerber Kawasaki Wealth & Investment Management Trims Holdings

Gerber Kawasaki Wealth & Investment Management decreased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 54.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,319 shares of the medical research company’s stock after selling 1,552 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Natera were worth $545,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. SYM FINANCIAL Corp increased its stake in Natera by 1.7% in the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company’s stock valued at $784,000 after purchasing an additional 32 shares in the last quarter. Versant Capital Management Inc raised its holdings in Natera by 4.6% during the third quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after purchasing an additional 36 shares during the last quarter. VestGen Advisors LLC boosted its position in Natera by 3.1% during the third quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company’s stock worth $603,000 after purchasing an additional 44 shares in the last quarter. Parallel Advisors LLC boosted its position in Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after purchasing an additional 47 shares in the last quarter. Finally, Raiffeisen Bank International AG boosted its position in Natera by 48.5% during the second quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock worth $41,000 after purchasing an additional 49 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 15,160 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the sale, the insider owned 110,859 shares of the company’s stock, valued at $36,238,698.51. This trade represents a 12.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of Natera stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $425.55, for a total value of $811,098.30. Following the sale, the chief financial officer owned 46,574 shares of the company’s stock, valued at approximately $19,819,565.70. This represents a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 45,256 shares of company stock valued at $16,455,344. 5.05% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Piper Sandler upped their target price on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Rothschild & Co Redburn assumed coverage on Natera in a research note on Tuesday, September 8th. They set a “buy” rating and a $385.00 price target for the company. Guggenheim boosted their price objective on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Stephens increased their price objective on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Canaccord Genuity Group raised their target price on shares of Natera from $375.00 to $500.00 and gave the company a “buy” rating in a report on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $394.31.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Fresh evidence presented at the ESMO oncology meeting may strengthen Natera’s case for growth in cancer testing, broadening the potential opportunity for its oncology business. ESMO oncology data article
• Neutral Sentiment: Natera is due to report earnings on November 5, making results and management’s outlook a near-term catalyst. The report preview highlights investor expectations, but the supplied article details do not provide specific estimates. Earnings preview
• Neutral Sentiment: Analysts’ consensus target is $394.31, close to the share price cited in the market update, with an overall “Moderate Buy” rating. That suggests limited implied upside at that reference price, despite generally favorable ratings. Analyst target article
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small reduction make the sale less clear as a signal about the company’s outlook. Insider sale article
• Negative Sentiment: Reports described a steep recent share-price drop, indicating selling pressure and heightened investor caution ahead of earnings. The pullback may reflect elevated expectations or uncertainty about the results, though the headlines provided do not identify a specific cause. After-hours decline report

Natera Price Performance

Shares of Natera stock opened at $388.63 on Wednesday. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The company has a market capitalization of $56.02 billion, a P/E ratio of -285.76 and a beta of 1.55. The business has a 50 day moving average price of $379.22 and a 200 day moving average price of $267.89.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.74) EPS. As a group, research analysts expect that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.